Overview

Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors

Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study assesses the safety and efficacy of imatinib mesylate treatment of patients with malignant peripheral nerve sheath tumors
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Imatinib Mesylate